Abridge to add 10,000 Cochrane reviews to clinical AI assistant
The multi-year Wiley agreement brings cited medical evidence into a tool Abridge says is used across more than 300 U.S. health systems.

Abridge will add Cochrane evidence from nearly 10,000 systematic reviews to its clinical AI assistant under a multi-year Wiley licensing deal announced in a Nov. 16 press release.
The companies said the integration will put cited medical evidence into a workflow used across more than 300 U.S. health systems and expected to support more than 120 million patient encounters in 2026.
Wiley will license the Cochrane Database of Systematic Reviews and Cochrane Clinical Answers to Abridge for use in the Abridge Assistant, according to the press release. The companies said the content will appear as concise summaries with citations, while full text will be available to Wiley subscribers.
“Trusted evidence becomes even more useful when it connects to the context of care,” Shiv Rao, CEO and co-founder of Abridge, said in the release.
Armughan Rafat, chief AI and data analytics officer for Wiley, said clinicians need evidence they can check as AI tools enter routine practice. “Clinicians deserve evidence behind them they can trust, verify, and stand behind,” Rafat said.
The Abridge Assistant provides context-aware clinical decision support, according to the companies. In practice, that means the tool is designed to draw on a patient chart, the clinical conversation and medical evidence when responding to a clinician’s question.
Cochrane reviews are systematic reviews, a research method that evaluates bodies of evidence rather than single studies. Wiley will also license about 4,000 clinical answers, which the companies described as actionable insights drawn from Cochrane reviews.
The agreement is part of a broader push to embed evidence sources directly into clinical software rather than requiring clinicians to leave their workflow to search medical databases. The companies said the deal covers U.S. care-delivery organizations.
The announcement did not include financial terms, a deployment schedule, independent performance data for the integration or evidence that the tool changes clinical outcomes. Those limits matter because cited responses can improve transparency, but they do not by themselves establish accuracy, safety or clinical benefit.
Abridge said it was awarded Best in KLAS for Ambient AI in 2025 and 2026 and was named a CNBC Disruptor and a Fast Company Most Innovative Company in 2025. The companies said the partnership positions Wiley and Abridge to explore further uses of evidence-based content in clinical workflows.
Source: company press release, Abridge, Nov. 16, 2026
Atlas360 reports health research and does not provide medical advice.
More stories
- Europe faces attribution gap after 16 cyber, physical incidents
- PIF backs Grand Theft Auto as Saudi players embrace game
- Signal limits screenshots to curb AI access to messages
- Cognition runs Devin Mac workspaces on EC2 in 6 AWS regions
- Salesforce engineers cut 600-failure triage to 90 minutes
- Türkiye Desk: GTA 6 puts console access and network demand in focus
- Microsoft plans Project Helix as Xbox console for PC games
- OpenAI buys travel startup Odessia
- "Friction-maxxing "Silicon Valley Spent Billions Removing Friction. Now People Are Paying to Put It Back.
- AMD stock hits record as value crosses $1 trillion mark
Latest news
- David Parr House to honor Victorian art-workman with blue plaque
- Iran's attacks hit 25 tankers near Strait of Hormuz
- FCC approves prison cellphone jamming despite 2.5-mile warning
- Russia strikes Ukraine as Odesa faces electricity strain
- Bahrain reports two injuries after Iranian aerial attacks
- Congress tests Black Democrats' growing policy influence
- Baltic responders fight Sparta II fire after drone strike
- Dietitians advise small swaps for plant-based eating

